Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Metis TechBio Co's Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-17.47 Mil. Therefore, Metis TechBio Co's EV-to-EBIT ratio for today is -82.29.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Metis TechBio Co's Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €-16.38 Mil. Therefore, Metis TechBio Co's EV-to-EBITDA ratio for today is -87.77.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Metis TechBio Co's Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €0.41 Mil. Therefore, Metis TechBio Co's EV-to-Revenue ratio for today is 3,522.77.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Metis TechBio Co's Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-9.77 Mil. Therefore, Metis TechBio Co's EV-to-FCF ratio for today is -147.19.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Metis TechBio Co (FRA:RO9) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Metis TechBio Co's current Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.47 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Metis TechBio Co's current Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.38 Mil.
Metis TechBio Co's current Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.41 Mil.
Metis TechBio Co's current Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.64 Mil.
Metis TechBio Co's current Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co Enterprise Value Related Terms
Metis TechBio Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for Metis TechBio Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co Enterprise Value Chart
Metis TechBio Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Enterprise Value
0.00
0.00
0.00
0.00
Metis TechBio Co Quarterly Data
Dec22
Dec23
Dec24
Sep25
Dec25
Enterprise Value
0.00
0.00
0.00
0.00
0.00
FRA:RO9 vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Metis TechBio Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metis TechBio Co Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metis TechBio Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Metis TechBio Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Metis TechBio Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of €1,437.29 Mil mean?
Metis TechBio Co (FRA:RO9) has a Enterprise Value of €1,437.29 Mil as of Aug. 11, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Metis TechBio Co and its competitors.
Is Metis TechBio Co's Enterprise Value too high?
Metis TechBio Co's current Enterprise Value is €1,437.29 Mil. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's Enterprise Value compare to VRTX and REGN?
Metis TechBio Co's Enterprise Value of €1,437.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Metis TechBio Co and its competitors. Metis TechBio Co's current Enterprise Value is €1,437.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current Enterprise Value of €1,437.29 Mil. The current Enterprise Value is €1,437.29 Mil. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current Enterprise Value is €1,437.29 Mil as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score
Get the complete analysis for FRA:RO9
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RO9 has been successfully added to your 
